Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer

N J Hawkins, I Tomlinson, A Meagher, R L Ward, N J Hawkins, I Tomlinson, A Meagher, R L Ward

Abstract

Chromosomal instability and microsatellite instability represent the major pathways for colorectal cancer (CRC) progression. However, a significant percentage of CRC shows neither pattern of instability, and thus represents a potentially distinctive form of the disease. Flow cytometry was used to determine the degree of DNA aneuploidy in 46 consecutive sporadic colorectal cancers. Microsatellite status was determined by PCR amplification using standard markers, while immunostaining was used to examine the expression of p53. K- ras status was determined by restriction-mediated PCR assay. Twenty-five (54%) tumours were aneuploid, 14 (30%) were diploid and microsatellite-stable and seven (15%) were diploid and microsatellite-unstable. Tumours with microsatellite instability were more likely to be right sided, to occur in women and to be associated with an improved survival. Aneuploid tumours were significantly more common in men and were likely to be left sided. The diploid microsatellite-stable (MSS) tumours did not show a sex or site predilection, but were strongly associated with the presence of metastatic disease at the time of diagnosis. Our data suggests that diploid, MSS tumours represent a biologically and phenotypically distinct subset of colorectal carcinoma, and one that is associated with the early development of metastases. We suggest that the genetic stability that characterizes these tumours may favour the maintenance of an invasive phenotype, and thus facilitate disease progression. These findings may have important implications for treatment options in this disease subset.

Copyright 2001 Cancer Research Campaign.

References

    1. Cancer. 1997 Mar 15;79(6):1106-13
    1. Cancer. 1997 Jan 15;79(2):233-44
    1. Cancer. 1998 Jan 1;82(1):49-59
    1. Surgery. 1998 Jan;123(1):13-8
    1. Cancer Res. 1998 Apr 15;58(8):1713-8
    1. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5
    1. Gut. 1998 May;42(5):673-9
    1. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702
    1. Am J Pathol. 1998 Aug;153(2):373-9
    1. Oncogene. 1998 Aug 13;17(6):719-25
    1. Am J Pathol. 1998 Oct;153(4):1063-78
    1. Cancer Res. 1998 Nov 15;58(22):5248-57
    1. Hepatogastroenterology. 1998 Sep-Oct;45(23):1573-8
    1. Dig Surg. 1998;15(6):687-92
    1. Eur J Surg. 1999 Apr;165(4):363-8
    1. J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303
    1. J Clin Oncol. 1999 Aug;17(8):2429-38
    1. Cytometry. 1999 Dec 15;38(6):293-300
    1. Oncogene. 1999 Dec 23;18(56):7933-40
    1. Eur J Cancer Prev. 1999 Dec;8 Suppl 1:S13-20
    1. Lancet. 2000 May 20;355(9217):1745-50
    1. Cancer Genet Cytogenet. 1984 Oct;13(2):181-3
    1. Mod Pathol. 1990 Nov;3(6):709-12
    1. Cancer. 1991 Aug 15;68(4):879-88
    1. Eur J Surg Oncol. 1992 Dec;18(6):585-90
    1. Science. 1993 May 7;260(5109):810-2
    1. Science. 1993 May 7;260(5109):816-9
    1. Nature. 1993 Jun 10;363(6429):558-61
    1. Cytometry. 1993;14(5):486-91
    1. Am J Pathol. 1994 Jul;145(1):148-56
    1. Histopathology. 1996 Jun;28(6):543-8
    1. Am J Pathol. 1997 May;150(5):1815-25

Source: PubMed

3
Subscribe